NOTE: STATUS CHANGE ON AN EXISTING NEWSGROUP - UNMODERATED TO MODERATED. Information for VIROLOGY/bionet.virology (moderated) USENET newsgroup name: bionet.virology Status: Moderated One line Description: Research into virology. Moderation address: bionet-virology@net.bio.net (virology-moderator@net.bio.net is an alias for bionet-virology@net.bio.net) Moderators: Brett Lindenbach Mailing list name: VIROLOGY E-mail address: virology@net.bio.net Newsgroup Charter: It is the intention to use bionet.virology as a group for: (a) the posting of information relating to: (1) Virus taxonomy (2) Virus structure and morphogenesis (3) Multiplication of viruses (4) Virus genetics and evolution (5) Epidemiology and Pathogenesis of viruses (6) Host response to viral infections (7) Vaccinology and antiviral chemotherapy (8) Any other matters pertaining to viruses not mentioned above (9) Discussion on journal publications in topics listed above (10) Requests for information in the topics listed above Whilst the group name is virology and the charter above only mentions viruses, postings in the above categories about infectious agents such as viroids and prions are to be included in this group. Discussion about evolution should be restricted to viral evolution only. (b) the posting of news on methods or reagents relating to techniques used uniquely for or with viruses It is not intended to include postings on methods or reagents common to molecular biology. These are better placed in bionet.molbio.methds-reagnts. (c) the posting of articles from various 'non-journal' publications such as CDI weekly, and other infectious diseases bulletins and the various virus newsletters (eg Virus Information Exchange Newsletter) (d) the posting of articles relating to current outbreaks of viral disease around the world Moderation Policy: Mass-posted commercial messages, chain letters, and similar postings not germane to the newsgroup's charter will be deleted without comment. Inappropriate messages posted in good faith will be returned to the sender.